Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125252581 | 12525258 | 1 | I | 20160517 | 20160624 | 20160704 | 20160704 | EXP | FR-PFIZER INC-2016317042 | PFIZER | 16.00 | YR | M | Y | 0.00000 | 20160704 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125252581 | 12525258 | 1 | PS | SOLU-MEDROL | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous drip | 55 MG, DAILY | 11856 | 55 | MG | ||||||||
| 125252581 | 12525258 | 2 | SS | Zyvoxid | LINEZOLID | 1 | Oral | 400 MG, 2X/DAY | 12000 | MG | Y | 21131 | 400 | MG | BID | ||||
| 125252581 | 12525258 | 3 | SS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous drip | UNK | Y | 71484 | SOLUTION FOR INJECTION | ||||||||
| 125252581 | 12525258 | 4 | SS | ICLUSIG | PONATINIB | 1 | Oral | 30 MG, 1X/DAY | 6480 | MG | Y | 0 | 30 | MG | FILM-COATED TABLET | QD | |||
| 125252581 | 12525258 | 5 | SS | ICLUSIG | PONATINIB | 1 | Oral | 45 MG, 1X/DAY | 6480 | MG | Y | 0 | 45 | MG | FILM-COATED TABLET | QD | |||
| 125252581 | 12525258 | 6 | SS | ICLUSIG | PONATINIB | 1 | Oral | 30 MG, 1X/DAY | 6480 | MG | Y | 0 | 30 | MG | FILM-COATED TABLET | QD | |||
| 125252581 | 12525258 | 7 | SS | ICLUSIG | PONATINIB | 1 | Oral | 45 MG, 1X/DAY | 6480 | MG | Y | 0 | 45 | MG | FILM-COATED TABLET | QD | |||
| 125252581 | 12525258 | 8 | C | ZELITREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | UNK | 0 | ||||||||||
| 125252581 | 12525258 | 9 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, 2X/DAY | 84 | MG | 0 | 4 | MG | BID | |||||
| 125252581 | 12525258 | 10 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, 3X/DAY | 84 | MG | 0 | 4 | MG | TID | |||||
| 125252581 | 12525258 | 11 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, 2X/DAY | 84 | MG | 0 | 4 | MG | BID | |||||
| 125252581 | 12525258 | 12 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, 1X/DAY | 84 | MG | 0 | 4 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125252581 | 12525258 | 2 | Infection |
| 125252581 | 12525258 | 3 | Acute lymphocytic leukaemia |
| 125252581 | 12525258 | 4 | Acute lymphocytic leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125252581 | 12525258 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125252581 | 12525258 | Dyspepsia | |
| 125252581 | 12525258 | Hepatocellular injury | |
| 125252581 | 12525258 | Scleroderma |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125252581 | 12525258 | 1 | 20160503 | 20160511 | 0 | |
| 125252581 | 12525258 | 2 | 20160503 | 20160517 | 0 | |
| 125252581 | 12525258 | 3 | 20160507 | 20160507 | 0 | |
| 125252581 | 12525258 | 4 | 20151001 | 20160503 | 0 | |
| 125252581 | 12525258 | 5 | 20160504 | 20160524 | 0 | |
| 125252581 | 12525258 | 6 | 20160524 | 20160607 | 0 | |
| 125252581 | 12525258 | 7 | 20160607 | 0 | ||
| 125252581 | 12525258 | 10 | 20160511 | 20160517 | 0 | |
| 125252581 | 12525258 | 11 | 20160517 | 20160524 | 0 | |
| 125252581 | 12525258 | 12 | 20160524 | 20160602 | 0 |